scholarly article | Q13442814 |
P50 | author | Emily C Williams | Q79205279 |
P2093 | author name string | Judith I Tsui | |
Feng Su | |||
George N Ioannou | |||
Kristin Berry | |||
Pamela K Green | |||
P2860 | cites work | The validity of viral hepatitis and chronic liver disease diagnoses in Veterans Affairs administrative databases | Q45332145 |
Predictors of response of US veterans to treatment for the hepatitis C virus | Q45332298 | ||
Implementation of evidence-based alcohol screening in the Veterans Health Administration. | Q45332595 | ||
The effect of HIV coinfection on the risk of cirrhosis and hepatocellular carcinoma in U.S. veterans with hepatitis C. | Q45333263 | ||
Management of hepatitis C virus infection in heavy drinkers | Q45352065 | ||
The prevalence of cirrhosis and hepatocellular carcinoma in patients with human immunodeficiency virus infection | Q45358076 | ||
Alcohol use and treatment of hepatitis C virus: results of a national multicenter study | Q45416751 | ||
Influence of alcohol on the progression of hepatitis C virus infection: a meta-analysis | Q45422773 | ||
Independent and combined action of hepatitis C virus infection and alcohol consumption on the risk of symptomatic liver cirrhosis | Q45756849 | ||
AUDIT-C scores as a scaled marker of mean daily drinking, alcohol use disorder severity, and probability of alcohol dependence in a U.S. general population sample of drinkers. | Q48443347 | ||
FIB-4: An inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest | Q62658359 | ||
Hepatitis C and alcohol | Q80983273 | ||
The AUDIT alcohol consumption questions (AUDIT-C): an effective brief screening test for problem drinking. Ambulatory Care Quality Improvement Project (ACQUIP). Alcohol Use Disorders Identification Test | Q28282539 | ||
The prevalence of hepatitis C virus infection in the United States, 1999 through 2002 | Q29619974 | ||
Effectiveness of Sofosbuvir, Ledipasvir/Sofosbuvir, or Paritaprevir/Ritonavir/Ombitasvir and Dasabuvir Regimens for Treatment of Patients With Hepatitis C in the Veterans Affairs National Health Care System | Q30841159 | ||
Who has diabetes? Best estimates of diabetes prevalence in the Department of Veterans Affairs based on computerized patient data | Q30926045 | ||
Alcohol use and hepatitis C. | Q34008546 | ||
Alcohol impairs interferon signaling and enhances full cycle hepatitis C virus JFH-1 infection of human hepatocytes | Q34258650 | ||
Systematic review: effect of alcohol intake on adherence to outpatient medication regimens for chronic diseases | Q34433709 | ||
Alcohol and hepatocellular carcinoma: the effect of lifetime intake and hepatitis virus infections in men and women | Q34520930 | ||
Quality concerns with routine alcohol screening in VA clinical settings. | Q34594514 | ||
Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C virus infection | Q34777639 | ||
Factors Underlying Quality Problems with Alcohol Screening Prompted by a Clinical Reminder in Primary Care: A Multi-site Qualitative Study | Q35876676 | ||
Chronic hepatitis C virus infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010 | Q36035889 | ||
The impact of lifetime alcohol use on hepatitis C treatment outcomes in privately insured members of an integrated health care plan | Q36185899 | ||
Ethanol metabolism alters major histocompatibility complex class I-restricted antigen presentation in liver cells | Q37162792 | ||
Prevalence of clinically recognized alcohol and other substance use disorders among VA outpatients with unhealthy alcohol use identified by routine alcohol screening. | Q38173126 | ||
Prevalence and treatment of chronic hepatitis C virus infection in the US Department of Veterans Affairs | Q38323723 | ||
Local Implementation of Alcohol Screening and Brief Intervention at Five Veterans Health Administration Primary Care Clinics: Perspectives of Clinical and Administrative Staff. | Q38387392 | ||
Hepatitis C and hospital outcomes in patients admitted with alcohol-related problems | Q39733097 | ||
Association of Hepatitis C Virus With Alcohol Use Among U.S. Adults: NHANES 2003-2010. | Q39766673 | ||
Trends in burden of cirrhosis and hepatocellular carcinoma by underlying liver disease in US veterans, 2001-2013. | Q40645393 | ||
Rising Mortality Associated With Hepatitis C Virus in the United States, 2003-2013. | Q40769735 | ||
Restrictions for Medicaid Reimbursement of Sofosbuvir for the Treatment of Hepatitis C Virus Infection in the United States | Q40786866 | ||
Concordance of sustained virological response 4, 12, and 24 weeks post-treatment with sofosbuvir-containing regimens for hepatitis C virus | Q41701742 | ||
Predictors of early treatment discontinuation among patients with genotype 1 hepatitis C and implications for viral eradication | Q42943658 | ||
Hepatitis C infection and alcohol use: A dangerous mix for the liver and antiviral immunity | Q42999228 | ||
Importance of patient, provider, and facility predictors of hepatitis C virus treatment in veterans: a national study | Q43001380 | ||
Utilization of surveillance for hepatocellular carcinoma among hepatitis C virus-infected veterans in the United States | Q43033283 | ||
Incidence and predictors of hepatocellular carcinoma in patients with cirrhosis | Q43037842 | ||
Treatment outcome in relation to alcohol consumption during hepatitis C therapy: an analysis of the Swiss Hepatitis C Cohort Study. | Q43119790 | ||
Two brief alcohol-screening tests From the Alcohol Use Disorders Identification Test (AUDIT): validation in a female Veterans Affairs patient population | Q44403557 | ||
The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. | Q44979610 | ||
P407 | language of work or name | English | Q1860 |
P921 | main subject | hepatitis C | Q154869 |
Hepatitis C virus | Q708693 | ||
alcohol consumption | Q2647488 | ||
P304 | page(s) | 101-109 | |
P577 | publication date | 2016-10-22 | |
P1433 | published in | Drug and Alcohol Dependence | Q5308875 |
P1476 | title | Alcohol use and hepatitis C virus treatment outcomes among patients receiving direct antiviral agents | |
P478 | volume | 169 |
Q89560966 | Alcohol Use and Long-Term Outcomes Among U.S. Veterans Who Received Direct-Acting Antivirals for Hepatitis C Treatment |
Q47554322 | Co-existing Hepatitis C and Alcoholic Liver Disease: A Diminishing Indication for Liver Transplantation? |
Q59354016 | Development of models estimating the risk of hepatocellular carcinoma after antiviral treatment for hepatitis C |
Q92464092 | Eradication of Hepatitis C Virus Is Associated With Reduction in Hematologic Malignancies: Major Differences Between Interferon and Direct-Acting Antivirals |
Q40050150 | HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma |
Q91801771 | Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases-Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection |
Q57166986 | Hepatitis C elimination among people who inject drugs: Challenges and recommendations for action within a health systems framework |
Q59350262 | Influence of comorbid drug use disorder on receipt of evidence-based treatment for alcohol use disorder among VA patients with alcohol use disorder and Hepatitis C and/or HIV |
Q59353966 | No difference between direct-acting antivirals for hepatitis C in hepatocellular carcinoma risk |
Q38775528 | Primary Care and Hepatology Provider-Perceived Barriers to and Facilitators of Hepatitis C Treatment Candidacy and Adherence |
Q90307952 | Psychosocial interventions to reduce alcohol consumption in concurrent problem alcohol and illicit drug users |
Q54213589 | Receipt of alcohol-related care among patients with HCV and unhealthy alcohol use. |
Q58769427 | S100B and Inflammatory Cytokine Levels in Blood as Potential Markers of Blood-Brain Barrier Damage and Psychiatric Impairment in Comorbid Hepatitis C Viral Infection and Alcohol Use Disorder |
Q90601704 | Untreated alcohol use disorder in people who inject drugs (PWID) in France: a major barrier to HCV treatment uptake (the ANRS-FANTASIO study) |